Varithena (polidocanol injectable foam) / Boston Scientific - LARVOL DELTA

1% polidocanol endovenous microfoam (VarithenaTM) for the treatment of chronic venous disease: A position statement from the American vein and lymphatic society. (PubMed, Phlebology) - "Despite the benefits across the spectrum of chronic venous disease, PEM may have advantages in minimizing the risk of nerve injury associated with treatment of the below knee reflux, treating venous ulcers, and managing recurrent varicose veins and difficult saphenous anatomy due to tortuosity or intraluminal synechia.ConclusionAs the only FDA approved foam sclerosant, PEM provides flexibility in treating patients with standard, variant, and recurrent venous anatomy. The American Vein and Lymphatic Society supports PEM as a safe and effective treatment option for the treatment of C2-C6 disease associated with superficial venous reflux."

Journal • Review • Cardiovascular • Varicose Veins • Venous Ulcer

Early experience managing intravascular coagulum using polidocanol endovenous microfoam: Risk factor analysis. (PubMed, Phlebology) - "Lower polidocanol endovenous microfoam injection volumes is a risk factor for developing intravascular coagulum. Further studies are needed to identify the ideal injection volume per segment of vein treated."

Journal • Cardiovascular • Pain

Radiofrequency Ablation Versus Polidocanol Endovenous Microfoam Ablation Of Large Diameter Saphenous And Tributary Veins (VEITH 2024) - No abstract available

Varithena®VLU Registry: Update On The Effects Of Polidocanol Endovenous Microfoam On Wound Healing And Recurrence (VEITH 2024) - No abstract available

Truncal Vein Treatment For Chronic Venous Disease: Is Varithena Endovenous Ablation Or Physician Compounded Foam The Answer (VEITH 2024) - No abstract available

Varithena Meta-Analysis “RELOADED”, The Living Approach (VEITH 2024) - No abstract available

Retrospective data

Factors Associated With Recanalization And Reintervention Following Below Knee Polidocanol Endovenous Microfoam (VEITH 2024) - No abstract available

Non-Compounded Polidocanol 1% Endovenous Microfoam (Varithena) Or Thermal Ablation: A Network Meta-Analysis (VEITH 2024) - No abstract available

Retrospective data

Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS) (clinicaltrials.gov) - P4 | N=43 | Terminated | Sponsor: Boston Scientific Corporation | N=100 ➔ 43 | Trial completion date: Jun 2027 ➔ Apr 2024 | Active, not recruiting ➔ Terminated; Enrollment challenges and a difficult insurance coverage landscape

Enrollment change • Trial completion date • Trial termination • Varicose Veins

Comparative Effectiveness of Non-compounded Polidocanol 1% Endovenous Microfoam (Varithena) Ablation versus Endovenous Thermal Ablation: A Systematic Review and Network Meta-analysis. (PubMed, J Vasc Surg Venous Lymphat Disord) - "Polidocanol 1% endovenous microfoam was not statistically different from endovenous thermal ablation for venous closure and deep vein thrombosis risk for chronic venous insufficiency treatment, based on a network meta-analysis of published evidence. Polidocanol 1% endovenous microfoam was statistically significantly differentiated from physician-compounded foam, with higher odds of vein closure. A sensitivity analysis found venous closure findings were robust at follow-up intervals of 12 months or greater and up to 6 years. New evidence meeting inclusion criteria for this review will be incorporated at regular intervals to a living network meta-analysis."

HEOR • Journal • Retrospective data • Review • Cardiovascular • Hematological Disorders • Thrombosis • Varicose Veins • Venous Thromboembolism • Venous Ulcer

Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS) (clinicaltrials.gov) - P4 | N=100 | Active, not recruiting | Sponsor: Boston Scientific Corporation | Recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2024 ➔ Apr 2024

Enrollment closed • Trial primary completion date • Varicose Veins

VeinGlobal Superficial Vein Theater (IVC 2024) - "Devices include: Venclose, New ClosureFAST, 1470 nm laser (radial fiber and covered fiber), Clarivein, Varithena, and Venaseal. Perforator vein treatment (Maven device, Laser, Foam). Liquid and foam sclerotherapy of spider veins."

Clinical

Superficial Venous Disease - An updated review. (PubMed, Ann Vasc Surg) - "Superficial venous diseases (SVD) are prevalent and have varied manifestations predominantly in the lower extremities. Several studies highlight the growing clinical and financial burden of these diseases. This review provides an update on the pathophysiology, classification, clinical features, and imaging findings as well as the conservative, pharmacological, and interventional treatment options indicated for different SVD pathologies. It aims to expedite the timely deployment of therapies geared towards reducing the significant morbidity associated with SVD especially varicose veins, venous ulcers, and venous insufficiency, to improve the quality of life of these patients and prevent complications."

Journal • Review • Cardiovascular • Dermatitis • Dermatology • Hematological Disorders • Immunology • Thrombosis • Varicose Veins • Venous Thromboembolism • Venous Ulcer

Factors Associated with Recanalization and Reintervention Following Below Knee Polidocanol Endovenous Microfoam Ablation for Great Saphenous and Small Saphenous Veins. (PubMed, J Vasc Surg Venous Lymphat Disord) - "PEM is successful for the treatment of BK GSV and SSV reflux with a closure rate of 89% at a mean of 231 days and shows promise as salvage therapy. Most recanalizations were noted in the early post-procedure period and were associated with lower PEM volume. Larger vein diameter, male sex, and anticoagulation use are associated with higher rates of recanalization."

Journal

Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS) (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Boston Scientific Corporation | Trial completion date: Nov 2026 ➔ Jun 2027 | Trial primary completion date: Feb 2024 ➔ Sep 2024

Trial completion date • Trial primary completion date • Varicose Veins

Factors Associated with Ablation Related Thrombus Extension (ARTE) Following Microfoam Versus Radiofrequency Saphenous Vein Closure. (PubMed, J Vasc Surg Venous Lymphat Disord) - "Ablation related thrombus extension following above-knee GSV closure occurred more frequently following MFA. Our results suggest that a saphenous vein diameter greater than 10 mm may be associated with ARTE. Despite this finding, all patients with ARTE were treated with short-term anticoagulation with no related complications. Until larger studies with high-risk subgroups have been studied following MFA, DU should be performed routinely post-procedure and ARTE patients anticoagulated until the thrombus retracts caudal to the saphenofemoral junction or is no longer present on duplex. Current societal guidelines recommending against routine post-thermal ablation DU should not be applied to similar patients following saphenous non-thermal MFA ablation."

Journal • Thrombosis • Varicose Veins

CHRONIC WOUNDS LEADING TO CALCIPHYLAXIS OR VICE VERSA: A DIAGNOSTIC DILEMMA IN A PATIENT (CHEST 2023) - "The patient was following at the wound care clinic for these chronic ulcers and recently underwent left great saphenous vein ablation 2 months prior to presentation and previously left great saphenous vein chemical ablation with Varithena... The diagnosis of calciphylaxis despite normal renal function should be considered for chronic non-healing wounds. [1]"

Clinical • Calciphylaxis • Cardiovascular • CNS Disorders • Congestive Heart Failure • Dermatology • Heart Failure • Hematological Disorders • Hepatology • Infectious Disease • Inflammation • Movement Disorders • Multiple Sclerosis • Pain • Rare Diseases • Renal Disease • Restless Legs Syndrome • Septic Shock • Sleep Disorder • Thrombocytopenic Purpura • Venous Ulcer

From Complexity to Clarity: Navigating C2-C6 Disease with Varithena by Boston Scientific (UIP-AVLS 2023) - "Sponsored by Boston"

VERITAS Study: Polidocanol Endovenous Microfoam Versus Thermal (VEITH 2023) - No abstract available

Radiofrequency Ablation Versus Polidocanol Endovenous Microfoam Ablation Of Large Diameter Saphenous And Tributary Veins (VEITH 2023) - No abstract available

Outcome Of A Single Center Trial Comparing A Large Patient Cohort With Retrograde Administration Of Ultrasound-Guided Polidocanol Endovenous Microfoam Versus Endovenous Laser (VEITH 2023) - No abstract available

Clinical

Varithena® VLU Registry: The Effects Of Polidocanol Endovenous Microfoam On Wound Healing And Recurrence (VEITH 2023) - No abstract available

Results Of Truncal Vein Ablation Utilizing Polidocanol Endovenous Microfoam Delivered In A Retrograde Fashion (VEITH 2023) - No abstract available

Optimizing Treatment for Chronic Venous Insufficiency: The Power of Varithena (NCVH 2023) - "Sponsored by Boston Scientific: NON-CME"

Cardiovascular

Venclose, ClosureFAST, 1470 nm Laser (Radial Fiber and Covered Fiber) Clarivein, Venaseal, Varithena (IVC 2023) - No abstract available